1,024 results match your criteria American Journal of Cardiovascular Drugs[Journal]


Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.

Am J Cardiovasc Drugs 2022 May 21. Epub 2022 May 21.

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Background: Inclisiran is a novel, cholesterol-lowering therapy, with a long duration of effect, administered every 6 months (subcutaneously by a healthcare professional). In the ORION-10 trial in US patients with atherosclerotic cardiovascular disease (ASCVD) in addition to maximum tolerated statins, with or without ezetimibe, inclisiran demonstrated statistically significant reductions in low-density lipoprotein cholesterol (LDL-C) of up to 51%. This is the first peer-reviewed publication to investigate the price at which inclisiran is cost effective in the US. Read More

View Article and Full-Text PDF

Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis.

Am J Cardiovasc Drugs 2022 May 16. Epub 2022 May 16.

School of Business Administration, Shenyang Pharmaceutical University, Shenyang, 110016, Liaoning, China.

Background: The role of aspirin in cardiovascular primary prevention remains controversial. Moreover, evidence for the potential benefits of aspirin in patients with high cardiovascular risk remains limited.

Objective: The aim of this study was to explore the role of low-dose aspirin in primary prevention. Read More

View Article and Full-Text PDF

Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data.

Am J Cardiovasc Drugs 2022 May 16. Epub 2022 May 16.

Internal Medicine, Medical affairs, Pfizer, New York, NY, 10017, USA.

Relatively little is known about the influence of extreme body weight on the pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many disease states. While direct oral anticoagulants (DOACs) have an advantage over warfarin in that they do not require routine drug monitoring, some may regard this convenience as less compelling in obese patients. Some consensus guidelines discourage using DOACs in patients weighing > 120 kg or with a body mass index > 35-40 kg/m, given a sparsity of available data in this population and the concern that fixed dosing in obese patients might lead to decreased drug exposure and lower efficacy. Read More

View Article and Full-Text PDF

The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review.

Am J Cardiovasc Drugs 2022 Apr 18. Epub 2022 Apr 18.

Research & Early Development, MyoKardia, Inc., A Wholly Owned Subsidiary of Bristol Myers Squibb, 1000 Sierra Point Parkway, Brisbane, CA, 94005, USA.

Hypertrophic cardiomyopathy (HCM) is a chronic, progressive disease of the cardiomyocyte with a diverse and heterogeneous clinical presentation and course. This diversity and heterogeneity have added to the complexity of modeling the pathophysiological pathways that contribute to the disease burden. The development of novel therapeutic approaches targeting precise mechanisms within the underlying biology of HCM provides a tool to model and test these pathways. Read More

View Article and Full-Text PDF

Atrial Fibrillation Management: A Comprehensive Review with a Focus on Pharmacotherapy, Rate, and Rhythm Control Strategies.

Am J Cardiovasc Drugs 2022 Mar 30. Epub 2022 Mar 30.

Center for Advanced Atrial Fibrillation Therapies at Aurora St. Luke's Medical Center, Milwaukee, WI, 53215, USA.

Atrial fibrillation (AF) is an increasingly common arrhythmia encountered in clinical practice that leads to a substantial increase in utilization of healthcare services and a decrease in the quality of life of patients. The prevalence of AF will continue to increase as the population ages and develops cardiac comorbidities; thus, prompt and effective treatment is important to help mitigate systemic resource utilization. Treatment of AF involves two tenets: prevention of stroke and systemic embolism and symptom control with either a rate or a rhythm control strategy. Read More

View Article and Full-Text PDF

Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy.

Am J Cardiovasc Drugs 2022 Mar 30. Epub 2022 Mar 30.

Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA.

Background: Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) experience infiltrative cardiomyopathy and heart failure symptoms requiring costly hospitalizations. The Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT) demonstrated the efficacy of tafamidis on the frequency of cardiovascular (CV)-related hospitalizations in patients with ATTR-CM.

Purpose: As length of stay can affect the total hospitalization burden, our study aimed to better understand the impact of tafamidis on the number of CV-related hospital days avoided in the management of ATTR-CM patients. Read More

View Article and Full-Text PDF

Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.

Am J Cardiovasc Drugs 2022 Mar 30. Epub 2022 Mar 30.

Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Background: The effects of sacubitril/valsartan in patients with chronic heart failure with reduced ejection fraction (HFrEF) were recently reported. However, the hemodynamic impact of this well-established treatment in patients with HFrEF has been poorly systematically researched.

Aim: We aimed to investigate the hemodynamic effects of sacubitril/valsartan among patients with HFrEF. Read More

View Article and Full-Text PDF

Correction to: Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use.

Authors:
Yahiya Y Syed

Am J Cardiovasc Drugs 2022 May;22(3):355

Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.

View Article and Full-Text PDF

Safety and Effectiveness of Direct Oral Anticoagulants Versus Warfarin for Treating Left Ventricular Thrombus.

Am J Cardiovasc Drugs 2022 Mar 29. Epub 2022 Mar 29.

Department of Cardiology, Kaiser Permanente Los Angeles Medical Center, 1526 North Edgemont Street, 2nd Floor, Los Angeles, CA, 90027, USA.

Background: Patients with left ventricular thrombus are at high risk for ischemic stroke and systemic embolization. The mainstay of treatment is anticoagulation, but it remains unclear if direct-acting oral anticoagulants (DOACs) are a safe and effective treatment strategy compared to warfarin. We conducted a population-based retrospective cohort study to evaluate the effectiveness and safety of DOACs compared to warfarin in an integrated health system in the United States. Read More

View Article and Full-Text PDF

Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.

Am J Cardiovasc Drugs 2022 May 22;22(3):299-323. Epub 2022 Mar 22.

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of anti-hyperglycemic drugs that has been steadily increasing in popularity due to its cardiovascular and renal benefits. Dual SGLT1/SGLT2 (SGLT1/2) inhibitors have potentially augmented anti-hyperglycemic action due to additional SGLT1 inhibition. This network meta-analysis aimed to compare the treatment effect across various outcomes between pure SGLT2 inhibitors and combined SGLT1/2 inhibitors in patients with diabetes. Read More

View Article and Full-Text PDF

Complementary Pharmacotherapy for STEMI Undergoing Primary PCI: An Evidence-Based Clinical Approach.

Am J Cardiovasc Drugs 2022 Mar 22. Epub 2022 Mar 22.

Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands.

Antithrombotic therapy is the cornerstone of pharmacological treatment in patients undergoing primary percutaneous coronary intervention (PCI). However, the acute management of ST elevation myocardial infarction (STEMI) patients includes therapy for pain relief and potential additional strategies for cardioprotection. The safety and efficacy of some commonly used treatments have been questioned by recent evidence. Read More

View Article and Full-Text PDF

The Effect of Vasopressin and Methylprednisolone on Return of Spontaneous Circulation in Patients with In-Hospital Cardiac Arrest: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Am J Cardiovasc Drugs 2022 Mar 22. Epub 2022 Mar 22.

Michigan State University, East Lansing, MI, USA.

Introduction: Cardiac arrest is often fatal if not treated immediately by cardiopulmonary resuscitation to restore a normal heart rhythm and spontaneous circulation. We aim to evaluate the clinical benefits of vasopressin and methylprednisolone versus placebo for patients with in-hospital cardiac arrest.

Data Sources: We searched PubMed, EMBASE, Scopus, Web of Science, Cochrane Central, and Google Scholar from inception to October 17, 2021, by using search terms included "Vasopressin" AND "Methylprednisolone" AND "Cardiac arrest". Read More

View Article and Full-Text PDF

Comparison of the Efficacy and Safety of Non-vitamin K Antagonist Oral Anticoagulants with Warfarin in Atrial Fibrillation Patients with a History of Bleeding: A Systematic Review and Meta-Analysis.

Am J Cardiovasc Drugs 2022 Mar 16. Epub 2022 Mar 16.

Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Background: Patients with atrial fibrillation (AF) require oral anticoagulation to prevent ischemic stroke. However, oral anticoagulation may cause bleeding, and patients with AF and a history of bleeding were excluded from pivotal trials comparing non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin. We therefore aimed to assess the efficacy and safety of NOACs compared with warfarin in patients with AF and a history of bleeding. Read More

View Article and Full-Text PDF

A Horse, a Jockey, and a Therapeutic Dilemma: Choosing the Best Option for a Patient with Diabetes and Coronary Artery Disease.

Am J Cardiovasc Drugs 2022 Mar 15. Epub 2022 Mar 15.

Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, 1 St. Kiriakidi Street, 54636, Thessaloníki, Greece.

Current guidelines for the management of hyperglycemia recommend the use of agents with proven cardiovascular (CV) benefit in patients with type 2 diabetes (T2D) and established CV disease. Although both glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) have been shown to reduce the risk of major adverse CV events (MACE) in high-risk populations with T2D, the ideal choice between the two classes for people with coronary artery disease remains controversial. SGLT2i reduce CV risk primarily through hemodynamic effects and changes in energy metabolism, making them the first choice in cases where heart failure or chronic kidney disease predominates. Read More

View Article and Full-Text PDF

Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use.

Authors:
Yahiya Y Syed

Am J Cardiovasc Drugs 2022 Mar 8;22(2):219-230. Epub 2022 Mar 8.

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

The single-pill combination (SPC) of perindopril (PER)/indapamide (IND)/amlodipine (AML) is a valuable and convenient treatment option for patients with hypertension controlled with two-drug SPC of PER/IND + AML given as two separate pills at the same dose level. PER [an angiotensin-converting enzyme (ACE) inhibitor], IND (a thiazide-like diuretic) and AML (a calcium channel blocker) are well established antihypertensive agents, which have been available for a long time as monotherapies and dual SPCs and have complementary mechanisms of action. Once-daily PER/IND/AML provided effective BP control, with good tolerability, in patients with uncontrolled hypertension in clinical trials and in large observational prospective studies. Read More

View Article and Full-Text PDF

A Comprehensive Approach to Managing Methamphetamine-Associated Cardiomyopathy.

Am J Cardiovasc Drugs 2022 Feb 14. Epub 2022 Feb 14.

St Vincent's Hospital Melbourne, Fitzroy, VIC, 3065, Australia.

Methamphetamines are illicit drugs of the amphetamine-type stimulant class that have been increasing in popularity, availability, and purity in recent decades. As a result, rates of methamphetamine-associated cardiomyopathy (MAC) are rising globally. MAC is associated with high rates of sudden cardiac arrest, late presentation, and poor outcomes. Read More

View Article and Full-Text PDF
February 2022

Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy.

Am J Cardiovasc Drugs 2022 Jan 29. Epub 2022 Jan 29.

Janssen Scientific Affairs, LLC, Titusville, NJ, USA.

Background: Current evidence suggests that rivaroxaban may be well tolerated and effective in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited evidence on the impact of polypharmacy in this population. This study evaluated real-world clinical outcomes with rivaroxaban versus warfarin in patients with NVAF and obesity according to the number of concurrent medications.

Methods: This retrospective cohort study identified patients with one or more pharmacy claim for rivaroxaban or warfarin from two large claims databases. Read More

View Article and Full-Text PDF
January 2022

A Multicenter Retrospective Evaluation of Direct Oral Anticoagulants for the Treatment of Heparin-Induced Thrombocytopenia.

Am J Cardiovasc Drugs 2022 Jan 18. Epub 2022 Jan 18.

Wake Forest Baptist, Atrium Health, 1 Medical Center Blvd, Winston-Salem, NC, 27157, USA.

Introduction: Direct oral anticoagulants (DOACs) represent an off-label but potential alternative to traditional therapies for heparin-induced thrombocytopenia (HIT).

Objective: The objective of this study was to evaluate the efficacy and safety of DOACs in patients with a diagnosis of laboratory-confirmed HIT.

Methods: A multicenter retrospective cohort study of adult patients with HIT treated with apixaban, rivaroxaban, or dabigatran between 1 January 2013 and 1 January 2020 was performed. Read More

View Article and Full-Text PDF
January 2022

Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future.

Am J Cardiovasc Drugs 2021 Dec 27. Epub 2021 Dec 27.

Postgraduate Program in Cardiology and Cardiovascular Sciences, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, School of Medicine, Rua Ramiro Barcelos 2350, Serviço de Fisiatria/Térreo, Porto Alegre, RS, 90470-260, Brazil.

Type 2 diabetes mellitus (T2DM) is associated with high cardiovascular morbidity and mortality, and cardiovascular diseases are the leading causes of death and disability in people with T2DM. Unfortunately, therapies strictly aimed at glycemic control have poorly contributed to a significant reduction in the risk of cardiovascular events. On the other hand, randomized controlled trials have shown that five glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and one exendin-based GLP-1 RA reduced atherosclerotic cardiovascular events in patients with diabetes at high cardiovascular risk. Read More

View Article and Full-Text PDF
December 2021

Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies.

Am J Cardiovasc Drugs 2021 Dec 20. Epub 2021 Dec 20.

College of Pharmacy, Yeungnam University, Gyeongsan, Gyeongbuk, Republic of Korea.

Introduction: Dyslipidemia in diabetes mellitus is characterized by hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and elevated low-density lipoprotein cholesterol (LDL-C). Additionally, the potentially increased risk of morbidity and mortality following atherosclerotic cardiovascular diseases should be considered in the treatment of dyslipidemia in patients with diabetes.

Methods: We performed a meta-analysis of the published data to compare the effects of HMG-CoA reductase inhibitor (statin)-ezetimibe combination therapy and statin monotherapy on lipid and glucose parameters in patients with diabetes. Read More

View Article and Full-Text PDF
December 2021

Comparison of Direct Oral Anticoagulants for Acute Hospital Mortality in Venous Thromboembolism.

Am J Cardiovasc Drugs 2021 Dec 20. Epub 2021 Dec 20.

Department of Cardiovascular Medicine, Tokushima University Hospital, 2-50-1 Kuramoto, Tokushima, Japan.

Background: The choice of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) is at the physician's discretion; however, it is useful to know the differences in the clinical data of DOACs to help physicians choose.

Objective: We aimed to compare the mortality associated with the use of rivaroxaban, edoxaban, and apixaban in clinical practice.

Methods: We identified 38,245 patients with first hospitalization for VTE from the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). Read More

View Article and Full-Text PDF
December 2021

Real-World Effectiveness of Ivabradine in Chinese Patients with Chronic Heart Failure: Interim Analysis of the POSITIVE Study.

Am J Cardiovasc Drugs 2022 May 8;22(3):345-354. Epub 2021 Dec 8.

Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, #180 Fenglin Road, Xuhui District, Shanghai, 200032, China.

Background: Ivabradine improves cardiac function and clinical outcomes in chronic heart failure (HF) by reducing heart rate (HR), but there is a lack of real-world data on its effectiveness and safety in Chinese patients.

Methods: We designed a prospective, multicenter, observational study of Chinese adults with HF and left ventricular systolic dysfunction, resting HR ≥ 75 beats per minute (bpm), and an indication for ivabradine treatment. An interim analysis was performed using a cut-off date of 31 October 2019. Read More

View Article and Full-Text PDF

Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension.

Am J Cardiovasc Drugs 2022 May 8;22(3):271-285. Epub 2021 Dec 8.

Department of Cardiology, The Mount Sinai Hospital, New York City, NY, USA.

Cardiovascular disease accounts for more than 17 million deaths globally every year, of which complications of hypertension account for 9.4 million deaths worldwide. Early detection and management of hypertension can prevent costly interventions, including dialysis and cardiac surgery. Read More

View Article and Full-Text PDF

Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.

Authors:
Hannah A Blair

Am J Cardiovasc Drugs 2022 Jan;22(1):109

Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.

View Article and Full-Text PDF
January 2022

Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis.

Am J Cardiovasc Drugs 2022 Jan 24;22(1):9-26. Epub 2021 Nov 24.

New York Medical College at Westchester Medical Center, New York, NY, USA.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus causing coronavirus disease 2019 (COVID-19), has affected human lives across the globe. On 11 December 2020, the US FDA granted an emergency use authorization for the first COVID-19 vaccine, and vaccines are now widely available. Undoubtedly, the emergence of these vaccines has led to substantial relief, helping alleviate the fear and anxiety around the COVID-19 illness for both the general public and clinicians. Read More

View Article and Full-Text PDF
January 2022

SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness.

Am J Cardiovasc Drugs 2022 May 17;22(3):263-270. Epub 2021 Nov 17.

Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128, Rome, Italy.

Heart failure (HF) represents a major global health and economic burden with still unacceptably high morbidity and mortality rates. In recent decades, novel therapeutic opportunities with a significant impact on HF outcomes have been introduced in addition to angiotensin-converting enzyme (ACE) inhibitors, β-blockers, and mineralocorticoid receptor antagonists. These include drugs such as ivabradine, sacubitril-valsartan, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Read More

View Article and Full-Text PDF

Improving the Management of Hypertension by Tackling Awareness, Adherence, and Clinical Inertia: A Symposium Report.

Am J Cardiovasc Drugs 2022 May 9;22(3):251-261. Epub 2021 Nov 9.

Service of Nephrology and Hypertension, University Hospital, Lausanne, Switzerland.

Hypertension remains the leading cause of global mortality, with elevated systolic blood pressure (BP) leading to 10.8 million deaths each year. Despite this, only around 50% of individuals with hypertension are aware of their condition. Read More

View Article and Full-Text PDF